Tumor-Specific Gene Editing Enhances Cancer Immunogenicity through Succinate Metabolism-Mediated MHC-I Reprogramming
Journal of the American Chemical Society · 11.11.2026 · 148 (44) · 48152-48167
DOI: 10.1021/jacs.6c14840 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Chemical Society, online erschienen am 02.11.2026. Verfasst von He Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The Second Affiliated Hospital of Soochow University, Suzhou215004, China. Hauptthemen laut MEDLINE: Gene Editing, Succinic Acid, Histocompatibility Antigens Class I. Die Arbeit nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Collaborative Innovation Center of Suzhou Nano Science and Technology, Higher Education Discipline Innovation Project.
Abstract (Originalsprache)
Impaired expression of major histocompatibility complex class I (MHC-I) greatly compromises cytotoxic T-cell-mediated anticancer immunotherapy. Existing MHC-I activation strategies are greatly challenged by poor tumor specificity and off-target toxicity. Herein, we report a dual tumor-specific CRISPR/Cas9 gene editing system that can precisely knock out succinate dehydrogenase subunit C (Sdhc) to activate the MHC-I pathway via epigenetic and transcriptional regulation. A tumor-specific gene editor is first engineered via reversible shielding of sgRNA using an apurinic/apyrimidinic endonuclease 1 (APE1)-responsive, complementary ssDNA, yielding AP-sgRNA with blocked editing activity in normal cells yet completely restored activity in APE1-overexpressing tumor cells. Subsequently, tumor-targeted delivery of AP-sgRNA and Cas9 mRNA (mCas9) is achieved using dibenzocyclooctyne-decorated lipid nanoparticle (DLNP), which upon bioorthogonal click reaction can anchor cancer cells that are prelabeled with azido groups using the unnatural sugar DCL-AAM. Thus, AP-sgSdhc/mCas9@DLNP enables efficient and selective Sdhc editing in tumor cells, leading to epigenetic and transcriptional activation of MHC-antigen processing and presentation genes and thereby provoking robust antitumor efficacy in the B16-OVA melanoma model through enhanced, T cell-mediated immune responses. Moreover, it completely suppressed pulmonary metastasis after combination with aPD-L1 in the 4T1 lung metastasis model. This study provides an enlightened paradigm for precision gene editing and renders a promising mechanism for potentiating cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The Second Affiliated Hospital of Soochow University, Suzhou215004, China.
- Institute of Functional Nano and Soft Materials (FUNSOM), Jiangsu Key Laboratory of Advanced Healthcare Materials and Devices, Soochow University, Suzhou215123, China.
- Surio Therapeutics Co., LTD., Hangzhou310024, China.
- School of Engineering, Westlake University, Hangzhou310024, China.
ORCID-Profile: Jianjun Cheng, Lichen Yin
Förderung
- National Natural Science Foundation of China
- Collaborative Innovation Center of Suzhou Nano Science and Technology
- Higher Education Discipline Innovation Project
- Joint International Research Laboratory of Carbon-Based Functional Materials and Devices
Zitieren
APA
Yang, H., Zhang, H., Zhao, Z., Ren, Y., Xu, Y., Cai, K., Cheng, J., Liu, X., Chen, Y., & Yin, L. (2026). Tumor-Specific Gene Editing Enhances Cancer Immunogenicity through Succinate Metabolism-Mediated MHC-I Reprogramming. Journal of the American Chemical Society, 148(44), 48152-48167. https://doi.org/10.1021/jacs.6c14840
Vancouver
Yang H, Zhang H, Zhao Z, Ren Y, Xu Y, Cai K, et al. Tumor-Specific Gene Editing Enhances Cancer Immunogenicity through Succinate Metabolism-Mediated MHC-I Reprogramming. Journal of the American Chemical Society. 2026;148(44):48152-48167. doi:10.1021/jacs.6c14840
BibTeX
@article{Yang2026,
author = {Yang, He and Zhang, Haoyu and Zhao, Ziyin and Ren, Yuxuan and Xu, Yanhan and Cai, Kaimin and Cheng, Jianjun and Liu, Xun and Chen, Yongbing and Yin, Lichen},
title = {Tumor-Specific Gene Editing Enhances Cancer Immunogenicity through Succinate Metabolism-Mediated MHC-I Reprogramming},
journal = {Journal of the American Chemical Society},
year = {2026},
volume = {148},
number = {44},
pages = {48152--48167},
doi = {10.1021/jacs.6c14840}
}
EUVIMED